Stemline Therapeutics (STML) Misses Q4 EPS by 1c

Stemline Therapeutics (NASDAQ: STML) reported Q4 EPS of ($0.58), $0.01 worse than the analyst estimate of ($0.57).

Stemline ended the fourth quarter of 2015 with $97.5 million in cash, cash equivalents and investments, as compared to $104.0 million as of September 30, 2015, which reflects a cash burn of $6.5 million for the quarter. The company ended the fourth quarter of 2015 with 18.2 million shares outstanding.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance
• Pony AI (PONY) Reports Revenue Above Estimates